AR017581A1 - Derivados de acido alfa-hidrocarboxilico heterociclicamente sustituido, su uso para la preparacion de una composicion farmaceutica, combinaciones dedichos derivados y una o mas sustancias activas, preparados farmaceuticos para la administracion peroral y parental y fragmento estructural comprendido - Google Patents
Derivados de acido alfa-hidrocarboxilico heterociclicamente sustituido, su uso para la preparacion de una composicion farmaceutica, combinaciones dedichos derivados y una o mas sustancias activas, preparados farmaceuticos para la administracion peroral y parental y fragmento estructural comprendidoInfo
- Publication number
- AR017581A1 AR017581A1 ARP980105651A ARP980105651A AR017581A1 AR 017581 A1 AR017581 A1 AR 017581A1 AR P980105651 A ARP980105651 A AR P980105651A AR P980105651 A ARP980105651 A AR P980105651A AR 017581 A1 AR017581 A1 AR 017581A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- sulfur
- phenyl
- oxygen
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados del ácido alfa-hidrocarboxílico heterocíclicamente sustituido segun formula (I) en donde R1 significa tetrazol o un grupo de formula II en dondeR tiene el siguiente significado: a) un resto OR5, en donde R5 significa: hidrogeno, el cation de un metal alcalino, el cation de un metal alcalinotérreo o union amonio orgánico fisiologicamente tolerable; cicloalquilo C3-8 alquilo C1-8, CH2-fenilo, alquenilo C3-8, alquilinilo-C3-8 o fenilo eventualmentesustituidos. b) un compuesto heteroaromático de 5 miembros, ligado a través de un átomo de nitrogeno, elegido entre: pirrolilo, pirazolilo, imidazolilo ytriazolilo, que pueden llevar uno o dos átomos de halogeno, o uno a dos grupos alquilo C1-4, o uno o dos grupos alcoxi C1-4 de formula (III), en la cual kpuede tomar los valores 0, 1 y 2, p los valores 1, 2, 3 y 4 y R6 representa: alquilo C1-4, cicloalquilo C3-8, alquenilo C3-8, alquinilo C3-8 o feniloeventualmente sustituido d) un resto de formula (IV) en donde R7 significa: alquilo-C1-4, alquenilo C3-8, alquinilo-C3-8, cicloalquilo-C3-8, pudiendo estosrestos llevar un resto alcoxi C1-4, alquiltio C1-4 y/o un resto fenilo; hologenoalquilo C1-4 o fenilo,eventualmente sustituido. A significa NR8R9, azido, OR10, SR10, o alquilo C1-4; X significa oxígeno, azufre, CR11 o NR12; con la condicion de que si X = CR11entonces Y=oxígeno o azufre o NR14. Y significa oxígeno, azufre, CR13 o NR14; con la condicion de que si Y = oxígeno o azufre o NR14;eentonces X =CR11. R2 y R3 (que pueden ser iguales o diferentes) significan: fenilo o naftilo, eventualmente sustituidos; ofenilo o naftilo; que pueden estar unidos entre sí en posicion orto a través de una ligadura directa, un grupo metileno, etileno o etenileno, un átomo deoxígeno oazufre o un grupo SO2, NH o N(alquilo C1-4); cicloalquilo C5-6, eventualmente sustituido; R4 y R11 (que pueden ser iguales o diferentes) significan:hidrogeno, halogeno, alcoxi C1-4, halogenoalcoxi C1-4, alqueniloxi C3-6, alquiniloxi C3-6, alquiltio C1-4, alquilcarbonilo C1-4, alcoxicarbonilo C1-4,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19750529A DE19750529A1 (de) | 1997-11-14 | 1997-11-14 | Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017581A1 true AR017581A1 (es) | 2001-09-12 |
Family
ID=7848772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105651A AR017581A1 (es) | 1997-11-14 | 1998-11-09 | Derivados de acido alfa-hidrocarboxilico heterociclicamente sustituido, su uso para la preparacion de una composicion farmaceutica, combinaciones dedichos derivados y una o mas sustancias activas, preparados farmaceuticos para la administracion peroral y parental y fragmento estructural comprendido |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6358983B1 (es) |
| EP (1) | EP1037883A1 (es) |
| JP (1) | JP2001523671A (es) |
| KR (1) | KR20010032083A (es) |
| CN (1) | CN1278805A (es) |
| AR (1) | AR017581A1 (es) |
| AU (1) | AU752165B2 (es) |
| BG (1) | BG104400A (es) |
| BR (1) | BR9814157A (es) |
| CA (1) | CA2308746A1 (es) |
| CO (1) | CO4990973A1 (es) |
| DE (1) | DE19750529A1 (es) |
| HR (1) | HRP980591A2 (es) |
| HU (1) | HUP0004341A3 (es) |
| ID (1) | ID24819A (es) |
| IL (1) | IL135461A0 (es) |
| NO (1) | NO20002154L (es) |
| NZ (1) | NZ504289A (es) |
| PL (1) | PL340756A1 (es) |
| SK (1) | SK4932000A3 (es) |
| TR (1) | TR200001365T2 (es) |
| WO (1) | WO1999025701A1 (es) |
| ZA (1) | ZA9810425B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
-
1997
- 1997-11-14 DE DE19750529A patent/DE19750529A1/de not_active Withdrawn
-
1998
- 1998-11-04 PL PL98340756A patent/PL340756A1/xx not_active Application Discontinuation
- 1998-11-04 SK SK493-2000A patent/SK4932000A3/sk unknown
- 1998-11-04 JP JP2000521084A patent/JP2001523671A/ja active Pending
- 1998-11-04 ID IDW20000882A patent/ID24819A/id unknown
- 1998-11-04 HU HU0004341A patent/HUP0004341A3/hu unknown
- 1998-11-04 CN CN98811085A patent/CN1278805A/zh active Pending
- 1998-11-04 IL IL13546198A patent/IL135461A0/xx unknown
- 1998-11-04 BR BR9814157-0A patent/BR9814157A/pt not_active IP Right Cessation
- 1998-11-04 TR TR2000/01365T patent/TR200001365T2/xx unknown
- 1998-11-04 CA CA002308746A patent/CA2308746A1/en not_active Abandoned
- 1998-11-04 EP EP98958900A patent/EP1037883A1/de not_active Withdrawn
- 1998-11-04 US US09/530,382 patent/US6358983B1/en not_active Expired - Fee Related
- 1998-11-04 WO PCT/EP1998/007026 patent/WO1999025701A1/de not_active Application Discontinuation
- 1998-11-04 AU AU14878/99A patent/AU752165B2/en not_active Ceased
- 1998-11-04 NZ NZ504289A patent/NZ504289A/en unknown
- 1998-11-04 KR KR1020007005207A patent/KR20010032083A/ko not_active Application Discontinuation
- 1998-11-09 AR ARP980105651A patent/AR017581A1/es not_active Application Discontinuation
- 1998-11-13 CO CO98067231A patent/CO4990973A1/es unknown
- 1998-11-13 ZA ZA9810425A patent/ZA9810425B/xx unknown
- 1998-11-13 HR HR19750529.5A patent/HRP980591A2/hr not_active Application Discontinuation
-
2000
- 2000-04-27 NO NO20002154A patent/NO20002154L/no not_active Application Discontinuation
- 2000-05-04 BG BG104400A patent/BG104400A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2308746A1 (en) | 1999-05-27 |
| CO4990973A1 (es) | 2000-12-26 |
| WO1999025701A1 (de) | 1999-05-27 |
| HRP980591A2 (en) | 1999-08-31 |
| ZA9810425B (en) | 2000-05-15 |
| SK4932000A3 (en) | 2001-02-12 |
| NO20002154L (no) | 2000-05-12 |
| CN1278805A (zh) | 2001-01-03 |
| BG104400A (en) | 2001-01-31 |
| NO20002154D0 (no) | 2000-04-27 |
| KR20010032083A (ko) | 2001-04-16 |
| BR9814157A (pt) | 2000-10-03 |
| IL135461A0 (en) | 2001-05-20 |
| ID24819A (id) | 2000-08-24 |
| DE19750529A1 (de) | 1999-05-20 |
| HUP0004341A1 (hu) | 2001-10-28 |
| JP2001523671A (ja) | 2001-11-27 |
| PL340756A1 (en) | 2001-02-26 |
| HUP0004341A3 (en) | 2001-12-28 |
| TR200001365T2 (tr) | 2000-09-21 |
| EP1037883A1 (de) | 2000-09-27 |
| US6358983B1 (en) | 2002-03-19 |
| NZ504289A (en) | 2002-03-01 |
| AU1487899A (en) | 1999-06-07 |
| AU752165B2 (en) | 2002-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
| EE9900156A (et) | Kondenseerunud 1-bensüül-3-(asendatud heteroarüül)pürasooli derivaadid | |
| AR057996A1 (es) | Compuestos, composiciones pesticidas y metodo par combatir pestes | |
| EA200200938A1 (ru) | Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение | |
| TR200003108T2 (tr) | İlaç kompozisyonları | |
| ATE375334T1 (de) | Harnstoff derivate als entzündungshemmende mittel | |
| ATE256681T1 (de) | N-heterozyklische derivate als nos inhibitoren | |
| BR0009200A (pt) | Compostos e composições para o tratamento dedoenças associada com disfunção imune | |
| TR200200843T2 (tr) | İşemi'nin Tedavisi için olan bileşikler | |
| BR9911013A (pt) | Derivados de pirazol como inibidores da p-38 map quinase | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| TR199802102T2 (xx) | Antifungal madde ve asetat tampon maddesi i�eren bile�imler. | |
| EE200100513A (et) | Rakkude adhesiooni inhibeerivad põletikuvastased ja immunosupressiivsed ühendid | |
| AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
| BR0007489A (pt) | Derivados de monossacarìdeos como inibidores de aderência celular | |
| AR005827A1 (es) | Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion | |
| AR017581A1 (es) | Derivados de acido alfa-hidrocarboxilico heterociclicamente sustituido, su uso para la preparacion de una composicion farmaceutica, combinaciones dedichos derivados y una o mas sustancias activas, preparados farmaceuticos para la administracion peroral y parental y fragmento estructural comprendido | |
| CO4900038A1 (es) | Nuevos derivados de acidos carboxilicos, su obtencion y aplicacion | |
| AR013360A1 (es) | Derivados de 6-azauracilo inhibidores de il-5, procedimiento para su preparacion, composicion que los contiene, procedimiento para preparardicha composicion, uso de dicho compuesto para la manufactura de medicamentos, de composiciones y procedimiento de marcado de un receptor. | |
| AR018632A1 (es) | Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion. | |
| EE9800233A (et) | Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena | |
| DE60222131D1 (de) | Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung | |
| AR014972A1 (es) | Derivados de piridina inhibidores de la fosfodiasterasa iv, un proceso para su preparacion, una composicion que los comprende y el uso de dichos derivadospara la preparacion de un medicamento | |
| DK0891346T3 (da) | Dihydrobenzofuranforbindelser, der er nyttige som antiinflammatoriske midler | |
| PA8444901A1 (es) | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |